Intrauterine misoprostol for the prevention of bleeding cesarean
Quiroga Díaz, R.; Cantú Mata, R.; Tello Gutiérrez, Héctor.E.; Puente Villalobos, M.; Montemayor Garza, R.; Martínez Mendoza, A.
Ginecologia y Obstetricia de Mexico 77(10): 469-474
2009
ISSN/ISBN: 0300-9041 PMID: 19902675 Document Number: 629542
To evaluate efficacy of misoprostol by intrauterine route for the prevention of the obstetrical hemorrhage and to know its effects collaterals. Clinical and randomized test with 200 patients to those who one took place to them Caesarean. The Group A was applied placebo and the group B misoprostol (group B; 800 microg) intrauterine, after the birth of its newborns. The necessity of additional uterotonics was compared, loss of hemoglobin and hematocrit, and the effects collaterals. In group B it diminished the necessity of additional uterotonics to 50% and the loss of hemoglobin in 39.6%. In the group greater loss of 3 was registered g of hemoglobin in 13 versus 3% of the patients. With respect to the hematocrit, its loss was reduced in 40.6%. The patients in those who the hematocrit in more fell than 10%, registered themselves in 7 versus 1% cases. The effects collaterals were few and not so serious. The intrauterine combination of misoprostol and oxitocin diminishes the postcaesarean sanguineous loss and has brings about few effects collaterals.